The relationship between DTCA, drug requests, and prescriptions: Uncovering variation in specialty and space

Marketing Science

Volumn 32, Issue 1, 2013, Pages 89-110

  Stremersch, Stefan ^a,b   Landsman, Vardit ^a,c   Venkataraman, Sriram ^d  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b IESE BUSINESS SCHOOL   (Spain)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Advertising; DTCA; Minorities; Pharmaceutical marketing; Prescriptions; Race origin; Requests; Sociodemographics

Indexed keywords

EID: 84873302922     PISSN: 07322399     EISSN: 1526548X     Source Type: Journal    
DOI: 10.1287/mksc.1120.0757     Document Type: Article

References (110)

1. AdAge (2011) U.S. ad spending grew 6.5% in 2010 as auto surged and pharma hit a low. (March 17), http://adage.com/article/mediaworks/u-s-ad-spending-grew-6-5-2010-auto-rose-pharma-fell/149436/.
2. Aikin KJ, Swasy JL, Braman AC (2004) Patient and physician attitudes and behaviors associated with DTC promotion of prescription drugs-Summary of FDA survey research results. Executive Summary, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC.
3. Amaldoss W, He C (2009) Direct-to-consumer advertising of prescription drugs: A strategic analysis. Marketing Sci. 28(3):472-487.
4. Armitage KJ, Schneidermann LJ, Bass RA (1979) Response of physicians to medical complaints in men and women. J. Amer. Medical Assoc. 241(20):2186-2187.
5. Atherly A, Rubin PH (2009) The cost-effectiveness of direct-toconsumer advertising for prescription drugs. Medical Care Res. Rev. 66(6):639-657.
6. Ayanian J, Epstein A (1991) Differences in the use of procedures between women and men hospitalized for coronary artery disease. New England J. Medicine 325(4):221-225.
7. Bajari P (2003) A comment on Allenby, Chen and Yang. Quant. Marketing Econom. 1(2):277-283.
8. Barg FK, Greir SA (2008) Enhancing breast cancer communications: A cultural models approach. Internat. J. Res. Marketing 25(4):335-342.
9. Bell RA, Kravitz RL, Wilkes MS (1999a) Direct-to-consumer prescription drug advertising and the public. J. General Internal Medicine 14(11):651-657.
10. Bell RA, Wilkes MS, Kravitz RL (1999b) Advertisement-induced prescription drug requests: Patients' anticipated reactions to a physician who refuses. J. Family Practice 48(6):446-452.
11. Berger JT, Kark P, Rosner F, Packer S, Bennett AJ (2001) Direct to consumer drug marketing: Public service or disservice? Mount Sinai J. Medicine 68(3):197-202.
12. Berry ST (1994) Estimating discrete-choice models of product differentiation. RAND J. Econom. 25(2):242-262.
13. Berry ST (2003) Comment on "Bayesian analysis of simultaneous demand and supply" by Sha Yang, Yuxin Chen, Greg M. Allenby. Quant. Marketing Econom. 1(3):285-291.
14. Berry ST, Levinsohn J, Pakes A (1995) Automobile prices in market equilibrium. Econometrica 63(4):841-890.
15. Bowser R (2001) Racial profiling in health care: An institutional analysis of medical treatment. Michigan J. Race Law 7:79-133.
16. Brekke KR, Kuhn M (2006) Direct to consumer advertising in pharmaceutical markets. J. Health Econom. 25(1):102-130.
17. Brooks SP, Gelman A (1998) General methods for monitoring convergence of iterative simulations. J. Comput. Graph. Statist. 7(4):434-455.
18. Broyles RW, McAuley WJ, Baird-Holmes D (1999) The medically vulnerable: Their health risks, health status, and use of physician care. J. Health Care Poor Underserved 10(2):186-200.
19. Calabro S (2003) In DTC-free Europe, just as many patients ask for brand drugs. Medical Marketing Media 38(11):3.
20. Camacho N, Landsman V, Stremersch S (2010) The connected patient. Wuyts S, Dekimpe MG, Gijsbrecht E, Pieters R, eds. The Connected Customer: The Changing Nature of Consumer and Business Markets, Chapter 5 (Routledge Academic, London).
21. Calfee JE, Winston C, Stempski R (2002) Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. J. Law Econom. 45(S2):673-690.
22. Cantor J (2010) Does direct to consumer advertising of antidepressants affect visits to physicians? Working paper, Cornell University, Ithaca, NY.
23. Cartwright A (1998) Community and the public body in breast cancer media activism. Cultural Stud. 12(2):117-138.
24. Centers for Disease Control and Prevention (2010) Health, United States, 2010-With special feature on death and dying. Report, National Center for Health Statistics, U.S. Department of Health and Human Services, Hyattsville, MD.
25. Chintagunta P, Dubé J-P, Goh KY (2005) Beyond the endogeneity bias: The effect of unmeasured brand characteristics on household-level brand choice models. Management Sci. 51(5):832-849.
26. Cohen MG, Fonarow GC, Peterson ED, Moscucci M, Dai D, Hernandez AF, Bonow RO, Smith SC Jr (2010) Racial and ethnic differences in the treatment of acute myocardial infarction: Findings from the Get with the Guidelines Coronary Artery Disease Program. Circulation 121(21):2294-2301.
27. Cooper-Patrick L, Gallo JJ, Gonzales JJ, Vu HT, Powe NR, Nelson C, Ford DE (1999) Race, gender, and partnership in the patientphysician relationship. J. Amer. Medical Assoc. 282(6):583-589.
28. Coscelli A (2000) The importance of doctors' and patients' preferences in the prescription decision. J. Indust. Econom. 48(3):349-369.
29. Daugird AJ, Crowell K (2003) Do statins cause myopathy? J. Family Practice 52(12):973-977.
30. Deveugele M, Derese A, van den Brink A, Bensing J, De Maeseneer J (2002) Consultation length in general practice: Cross sectional study in six European countries. British Medical J. 325(7362):472-477.
31. Ding M, Eliashberg J (2008) A dynamic competitive forecasting model incorporating dyadic decision making. Management Sci. 54(4):820-834.
32. Donohue JM, Berndt ER (2004) Effects of direct-to-consumer advertising on medication choice: The case of antidepressants. J. Public Policy Marketing 23(2):115-127.
33. Draganska, Jain MD (2002) Structural models of competitive market behavior: An estimation approach using disaggregate data. Working paper, Stanford University, Stanford, CA.
34. Dubé JP, Chintagunta PK (2003) Comment on Bayesian analysis of simultaneous demand and supply. Quant. Marketing Econom. 1(3):293-298.
35. Fischer M, Albers S (2010) Patient- or physician-oriented marketing: What drives primary demand for prescription drugs? J. Marketing Res. 47(1):103-121.
36. Gould SJ (1988) Consumer attitudes toward health and health care: A differential perspective. J. Consumer Affairs 22(1):96-118.
37. Hannan EL, Kilburn H Jr, O'Donnell JF, Lukacik G, Shields EP (1991) Interracial access to selected cardiac procedures for patients hospitalized with coronary artery disease in New York state. Medical Care 29(5):430-441.
38. Hannan EL, van Ryn M, Burke J, Stone D, Kumar D, Arani D, Pierce W, et al. (1999) Access to coronary artery bypass surgery by race/ethnicity and gender among patients who are appropriate for surgery. Medical Care 37(1):68-77.
39. Helman CG (1994) Culture, Health and Illness, 3rd ed. (Butterworth- Heinemann Ltd., Oxford, UK).
40. Hildebrand V, Van Kerm P (2009) Income inequality and self-rated health status: Evidence from the European community household panel. Demography 46(4):805-825.
41. Hollon MF (1999) Direct-to-consumer marketing of prescription drugs: Creating consumer demand. J. Amer. Medical Assoc. 281(4):382-384.
42. Hooper EM, Comstock LM, Goodwin JM, Goodwin JS (1982) Patient characteristics that influence physician behavior. Medical Care 20(6):630-638.
43. Hosken D, Wendling B (2010) Informing the uninformed: How drug advertising affects check-up visits. Internat. J. Indust. Organ., ePub ahead of print December 2.
44. Iizuka T, Jin GZ (2005) The effect of prescription drug advertising on doctor visits. J. Econom. Management Strategy 14(3):701-727.
45. IMS Health (2002) IMS study: U.S. physicians responsive to patient requests for brand-name drugs. Press release (April 1), IMS Health, Fairfield, CT.
46. Janakiraman R, Dutta S, Sismeiro C, Stern P (2008) Physicians' persistence and its implications for their response to promotion of prescription drugs. Management Sci. 54(6):1080-1093.
47. Kaplan SH, Gandek B, Greenfield S, Rogers W, Ware JE (1995) Patient and visit characteristics related to physicians' participatory decision-making style. Medical Care 33(12):1176-1187.
48. Koch-Laking A, Park MK, Tweed E (2010) Does DTC advertising affect physician prescribing habits? Clinical Inquiries 59(11):649-650.
49. Kolsarici C, Vakratsas D (2010) Category-versus brand-level advertising messages in a highly regulated environment. J. Marketing Res. 47(6):1078-1089.
50. Kravitz RL (2000) Direct-to-consumer advertising of prescription drugs: Implications for the patient-physician relationship. J. Amer. Medical Assoc. 284(17):2244.
51. Kravitz RL, Bell RA, Azari R, Kelly-Reif S, Krupat E, Thom DH (2003) Direct observation of requests for clinical services in office practice: What do patients want and do they get it? Arch. Internal Medicine 163(14):1673-1681.
52. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P (2005) Influence of patients' requests for direct-to-consumer advertised antidepressants. J. Amer. Medical Assoc. 293(16):1995-2002.
53. Kremer STM, Bijmolt THA, Leeflang PSH, Wieringa JE (2008) Generalizations on the effectiveness of pharmaceutical promotional expenditures. Internat. J. Res. Marketing 25(4):234-246.
54. Lillie-Blanton M, Brodie M, Rowland D, Altman D, McIntosh M (2000) Race, ethnicity, and the health care system: Public perceptions and experiences. Medical Care Res. Rev. 57(Supplemet 1):218-235.
55. Ling DC, Berndt ER, Kyle MK (2002) Deregulating direct-toconsumer marketing of prescription drugs: Effects on prescription and over-the-counter product sales. J. Law Econom. 45(2):691-723.
56. Liu Q, Gupta S (2011) The impact of direct-to-consumer advertising of prescription drugs on physician visits and drug requests: Empirical findings and public policy implications. Internat J. Res. Marketing 28(3):205-217.
57. Lupton D (1997) Consumerism, reflexivity and the medical encounter. Social Sci. Medicine 45(3):373-381.
58. Macias W, Lewis LS (2003) A content analysis of direct to consumer (DTC) prescription drug Web sites. J. Advertising 32(4):43-55.
59. Mack J (2009) The empowered patient: What it means for pharma marketers. Pharma Marketing News 8(4):2-7.
60. Manchanda P, Rossi PE, Chintagunta PK (2005) Response modeling with nonrandom marketing-mix variables. J. Marketing Res. 41(4):467-478.
61. Manchanda P, Xie Y, Youn N (2008) The role of targeted communication and contagion in product adoption. Marketing Sci. 27(6):961-976.
62. Mastin T, Andsager JL, Choi J, Lee K (2007) Health disparities and direct-to-consumer prescription drug advertising: A content analysis of targeted magazine genres, 1992-2002. Health Comm. 22(1):49-58.
63. McKillen D (2002) Consumers depend on brand-specific Web sites for information. Medical Marketing Media 37(5):12-14.
64. McKinlay J (1996) Some contributions from the social system to gender inequalities in heart disease. J. Health Soc. Behav. 37(1):1-26.
65. Medical Marketing and Media (2002) DTC success measured by drug requests. Medical Marketing Media 37(6):6.
66. Meyerhoefer CD, Zuvekas SH (2008) The shape of demand: What does it tell us about direct-to-consumer marketing of antidepressants? B.E. J. Econom. Anal. Policy 8(2):Article 4.
67. Mintzes B, Barer ML, Kravitz RL, Bassett B, Lexchin J, Kazanjian A, Evans RG, Pan R, Marion SA (2003) How does directto-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Medical Assoc. J. 169(5):405-412.
68. Mizik N, Jacobson R (2004) Are physicians "easy marks"? Quantifying the effects of detailing and sampling on new prescriptions. Management Sci. 50(12):1704-1715.
69. Mundy A (2008) Making a name for drugs without using their names; Some ads highlight only Web addresses so side effects don't have to be listed. Wall Street Journal 29(August):B.1.
70. Musalem A, Bradlow E, Raju J (2008) Who's got the coupon? Estimating consumer preferences and coupon usage from aggregate data. J. Marketing Res. 45(6):715-730.
71. Nevo A (2001) Measuring market power in the ready-to-eat cereal industry. Econometrica 69(2):307-342.
72. Omonuwa SC (2001) Health disparity in black women: Lack of pharmaceutical advertising in black-vs. white-oriented magazines.J. Natl. Medical Assoc. 93(7-8):263-266.
73. Parnes B, Smith PC, Gilroy C, Quintela J, Emsermann CB, Dickinson LM, Westfall JM (2009) Lack of impact of directto-consumer advertising on the physician-patient encounter in primary care: A SNOCAP report. Ann. Family Medicine 7(1):41-46.
74. Paterniti DA, Fancher TL, Cipri CS, Timmermans S, Heritage J, Kravitz RL (2010) Getting to "no." Archives Internal Medicine 170(4):381-388.
75. Peterson E, Shaw L, DeLong E, Pryor D, Califf R, Mark D (1997) Racial variation in the use of coronary-revascularization procedures-Are the differences real? Do they matter? New Eng. J. Medicine 336(7):480-486.
76. Prosser H, Almonda S, Walley T (2003) Influences on GPs' decision to prescribe new drugs-The importance of who says what. Family Practice 20(1):61-68.
77. Rama JK, Singh J (2010) Pragmatic learning theory: An inquiryaction framework for distributed consumer learning in online communities. J. Consumer Res. 36(April):1058-1081.
78. Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG (2003) Demand effects of recent changes in prescription drug information. Cutler DM, Garber AM, eds. Frontiers in Health Policy Research, Vol. 6 (MIT Press, Boston), 1-26.
79. Schwartz RK, Soumerai SB, Avorn J (1989) Physician motivations for nonscientivic drug prescribing. Soc. Sci. Medicine 28(6):577-582.
80. Sehili S, Elbasha EH, Moriarty DG, Zack MM (2004) Inequalities in self-reported physical health in the United States, 1993-1999. Health Econom. 14(4):377-389.
81. Sonel AF, Good CB, Mulgund J, Roe MT, Gibler WB, Smith Jr, SC, Cohen MG, Pollack CV Jr, Ohman EM, Peterson ED (2005) Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: Insights from CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines?). Circulation 111:1225-1232.
82. Steingart R (1991) Sex differences in management of coronary artery disease. New England J. Medicine 325(4):221-225.
83. Stevenson FA, Barry AC, Britten N, Barber N, Bradley CP (2000) Doctor-patient communication about drugs: the evidence for shared decision making. Soc. Sci. Medicine 50:829-840.
84. Street Jr, RL, Buller DB (1988) Patients' characteristics affecting physician-patient nonverbal communication. Human Comm. Res. 15(1):60-90.
85. Street RL, Gordon HS, Ward MM, Krupat E, Kravitz RL (2005) Patient participation in medical consultations: Why some patients are more involved than others. Medical Care 43(10):960-969.
86. Stremersch S, Van Dyck W (2009) Marketing of the life sciences: A new framework and research agenda for a nascent field. J. Marketing 73(4):4-30.
87. Sudhir K (2001) Structural analysis of competitive pricing in the presence of a strategic retailer. Marketing Sci. 20(3):244-264.
88. Tamayo-Sarver JH, Hinze SW, Cydulka RK, Baker DW (2003) Racial and ethnic disparities in emergency department analgesic prescription. Amer. J. Public Health 93(12):2067-2073.
89. Tentler A, Silberman J, Paterniti DA, Kravitz RL, Epstein RM (2008) Factors affecting physicians' responses to patients' requests for antidepressants: Focus group study. J. General Internal Medicine 23(1):51-57.
90. Todd KH, Samaroo N, Hoffman JR (1993) Ethnicity as risk factor for inadequate emergency department analgesia. J. Amer. Medical Assoc. 269(12):1537-1539.
91. Uhlmann RF, Inui TS, Pecoraro RE, Carter WB (1988) Relationship of patient request fulfillment to compliance, glycemic control, and other health care outcomes in insulin-dependent diabetes. J. Internal Medicine 3(5):458-463.
92. Vakratsas D, Ambler T (1999) How advertising works: What do we really know? J. Marketing 63(1):26-43.
93. Van Ryn M, Burke J (2000) The effect of patient race and socioeconomic status on physicians' perceptions of patients. Soc. Sci. Medicine 50:813-828.
94. Venkataraman S, Stremersch S (2007) The debate on influencing doctors' decisions: Are drug characteristics the missing link? Management Sci. 53(11):1688-1701.
95. Ventres W, Gordon P (1990) Communication strategies in caring for the underserved. J. Health Care for the Poor and Underserved 1:305-314.
96. Villas-Boas JM, Winer RS (1999) Endogeneity in brand choice models. Management Sci. 45(October):1324-1338.
97. Villas-Boas JM, Zhao Y (2005) Retailer, manufacturers, and individual consumers: Modeling the supply side in the ketchup marketplace. J. Marketing Res. 42(1):83-95.
98. Wang SS (2008) Drug-safety data: Too much information? The Wall Street Journal 9(December):D.1.
99. Webb S, Lloyd M (1994) Prescribing and referral in general practice: A study of patients' expectations and doctors' actions. British J. General Practice 44:165-169.
100. Weiss MC, Fitzpatrick R, Scott DK, Goldacre MJ (1996) Pressures on the general practitioner and decisions to prescribe. Family Practice 13(5):432-438.
101. Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R (2004) Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Affairs W3(Suppl. Web Exclusives):82-95.
102. Welch Cline J, Young HN (2004) Marketing drugs, marketing health care relationships: A content analysis of visual cues in direct-to-consumer prescription drug advertising. Health Comm. 16(2):131-157.
103. Wenneker M, Epstein A (1989) Racial inequalities in the use of procedures for patients with ischemic heart disease in Massachusetts. J. Amer. Medical Assoc. 261(2):253-257.
104. Werner RM, Asch DA, Polsky D (2005) Racial profiling: The unintended consequences of coronary artery bypass graft report cards. Circulation 111:1257-1263.
105. Wilkes MS, Bell RA, Kravitz RL (2000) Direct-to-consumer prescription drug advertising: Trends, impact, and implications. Health Affairs 19(2):110-128.
106. Wosinska M (2005) Direct-to-consumer advertising and drug therapy compliance. J. Marketing Res. 42(3):323-332.
107. Yang S, Allenby G (2003) Modeling interdependent consumer preferences. J. Marketing Res. 40(3):282-294.
108. Yang S, Chen Y, Allenby G (2003) Bayesian analysis of simultaneous demand and supply. Quant. Marketing Econom. 1:251-275.
109. Young M, Klingle RS (1996) Silent partners in medical care: A cross-cultural study of patient participation. Health Comm. 8(1): 29-35.
110. Zachry WM, Shepherd MD, Hinich MJ, Wilson JP, Brown CM, Lawson KA (2002) Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. Amer. J. Health-System Pharmacy 59(1):42-49.